I. COMMENCED TRADING IN NOVEMBER | ||||||||
Company |
Date |
Date |
Shares/ |
Price |
Shares |
Lead, Other |
Gross |
Post- |
INITIAL OFFERINGS | ||||||||
There were no initial public offerings completed in November. | ||||||||
Total: $0M Number of IPOs in November: 0 Average value of November IPOs: $0M Number of IPOs in 2012: 12 Total raised in IPOs in 2012: $811M Average value of IPOs in 2012: $67.58M | ||||||||
Company |
Date |
Date |
Shares/ |
Price |
Shares |
Lead, Other |
Gross |
Post- |
FOLLOW-ON OFFERINGS | ||||||||
Array BioPharma Inc. (Boulder, Colo.; ARRY)1 |
1/13/12 |
11/9/12 |
18S |
$3.65 |
112.9 |
Jefferies |
$65.7 |
$412.1 |
Rexahn Pharmaceuticals Inc. (Rockville, Md.; NYSE:RNN)2 |
7/5/11 |
11/30/12 |
19.13S and W for 10.52S |
$0.33 |
114.5 |
Maxim Group LLC |
$6.3 |
$37.785 |
Total: $72M Number of follow-on offerings in November: 2 Average value of November follow-ons: $36M Number of follow-on offerings in 2012: 85 Total raised in follow-ons in 2012: $7,134.01M Average value of follow-ons in 2012: $83.92M | ||||||||
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange. @ This column reflects the shares outstanding following the offering, when disclosed. % Market capitalization is calculated based on the offering price. Currency conversions are based on exchange rates at the time of the deal. 1 Array's overallotment option: 2.7M shares. 2 Rexahn's overallotment option: 2.9M shares of stock and warrants exercisable for up to 1.6M shares. Each fixed combination will consist of one share and a warrant to purchase up to 0.55 of a share. |
II. FILED AND PENDING | ||||||
Company |
Date Filed |
Shares/Units (M) |
Price |
Shares Out |
Lead, Other Underwriters |
Gross (US$M) |
INITIAL OFFERINGS | ||||||
Audeo Oncology Inc. (San Francisco; AURX)1 |
7/6/12 |
3.25S |
$14-$16 |
10.8 |
Leerink Swann |
$49 |
Enanta Pharmaceuticals Inc. (Watertown, Mass.; ENTA) |
11/6/12 |
N/A |
N/A |
N/A |
J.P. Morgan |
$69 |
Globeimmune Inc. (Louisville, Colo.; GBIM) |
7/2/12 |
5S |
$11-$13 |
17.23 |
Wells Fargo Securities |
$60 |
KaloBios Pharmaceuticals Inc. (South San Francisco; KBIO) |
10/5/12 |
N/A |
N/A |
N/A |
Leerink Swann LLC |
$60 |
Oncomed Pharmaceuticals Inc. (Redwood City, Calif.; OMED) |
5/11/12 |
N/A |
N/A |
N/A |
Jefferies |
$115 |
OvaScience Inc. (Cambridge, Mass.; OTC BB) |
8/28/12 |
7.6S |
$5.50 |
14.26 |
N/A |
$41.8 (to selling stockholders) |
Paratek Pharmaceuticals Inc. (Boston; PRTK) |
9/27/12 |
N/A |
N/A |
N/A |
UBS Investment Bank Leerink Swann (co-lead) |
$92 |
Radius Health Inc. (Cambridge, Mass.; RDUS)21 |
2/8/12 |
N/A |
N/A |
N/A |
UBS Investment Bank |
$86.25 |
Rib-X Pharmaceuticals Inc. (New Haven, Conn.; RIBX)3 |
11/28/11 |
10S |
$6-$7 |
19.9 |
Deutsche Bank Securities |
$65 |
Stemline Therapeutics Inc. (New York; STML) |
4/2/12 |
3.5S |
$11-$13 |
N/A |
Oppenheimer & Co. |
$42 |
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange. General shelf registration statements are not included until action is taken on the filing. * Stock symbols for companies seeking to complete IPOs are proposed. @ This column reflects the shares outstanding following the offering, when disclosed. N/A = Not available, applicable or reported. The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the most recent closing stock price before the offering was announced. In some cases, the company has not disclosed the number of shares to be offered or a price range. Then, the value is the maximum aggregate offering price listed in the SEC filing. 1 Audeo's overallotment option: 487,500-shares. 2 Radius Health withdrew its pending IPO, due to market conditions, on Nov. 15. 3 Rib-X opted for a private financing in 2012. |